Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

45
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment.

bioRxiv : the preprint server for biology·2026
Same author

Vitellogenin Identified as a Novel Allergen in Tenebrio molitor: Evidence from an Occupational Asthma Case.

Journal of investigational allergology & clinical immunology·2026
Same author

Precision Medicine in Allergic Rhinitis and Conjunctivitis: Integrative Molecular Mapping of the Allergic Exposome in Spain (EXPOMOL Study).

Journal of investigational allergology & clinical immunology·2026
Same author

Impact of Cooking Methods on Egg Allergenicity: Clinical Insights and Protein Profiling.

Journal of investigational allergology & clinical immunology·2025
Same author

RAC1 signaling in prostate cancer: VAV GEFs take center stage.

Frontiers in cell and developmental biology·2025
Same author

Experimental models of pancreas cancer: what has been the impact for precision medicine?

The Journal of clinical investigation·2025
Same journal

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same journal

Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunities.

Molecular cancer research : MCR·2026
Same journal

CELF2 is a tumor suppressor that modulates SLC7A11 and promotes ferroptosis in stomach adenocarcinoma.

Molecular cancer research : MCR·2026
Same journal

MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer.

Molecular cancer research : MCR·2026
Same journal

Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancer.

Molecular cancer research : MCR·2026
Same journal

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.

Molecular cancer research : MCR·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.2K

Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.

Fiorella Magani1,2, Stephanie O Peacock1,2, Meghan A Rice1,2

  • 1Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, Florida.

Molecular Cancer Research : MCR
|August 17, 2017
PubMed
Summary
This summary is machine-generated.

Targeting androgen receptor splice variants (AR-Vs) in castration-resistant prostate cancer (CRPC) is crucial. Disrupting coactivator binding to AR-V7 significantly reduced CRPC cell growth and aggressiveness, offering a new therapeutic strategy.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Related Experiment Videos

Last Updated: Feb 24, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Castration-resistant prostate cancer (CRPC) is an aggressive, incurable malignancy.
  • Constitutively active androgen receptor splice variants (AR-Vs), such as AR-V7, drive CRPC progression and confer resistance to standard androgen deprivation therapy (ADT).
  • Vav3 acts as a coactivator, enhancing AR-V signaling in CRPC.

Purpose of the Study:

  • To investigate the therapeutic potential of disrupting the interaction between AR-V7 and its coactivators.
  • To evaluate the effect of inhibiting Vav3-AR-V7 interaction on CRPC cell behavior.

Main Methods:

  • Utilized mutational and biochemical studies to analyze the interaction between the Vav3 Diffuse B-cell lymphoma homology (DH) domain and AR-V7.
  • Expressed the Vav3 DH domain to disrupt coactivator binding to AR-V7.
  • Assessed the impact of this disruption on CRPC cell proliferation, apoptosis, migration, and morphology.

Main Results:

  • The Vav3 DH domain successfully disrupted the interaction between Vav3 and AR-V7, as well as AR-V7 with other coactivators (Src1, Vav2).
  • Disruption of coactivator binding significantly decreased CRPC cell proliferation, anchorage-independent growth, and migration.
  • Induced increased apoptosis and promoted morphological changes indicative of a less aggressive phenotype in CRPC cells.

Conclusions:

  • Inhibiting constitutively active AR-V signaling by disrupting coactivator binding represents a promising therapeutic strategy for CRPC.
  • Targeting AR-V-coactivator interactions offers a novel approach for treating CRPC, particularly in cases resistant to current therapies.